适用人群-话题@MedSci

#适用人群#

6篇内容 | 282人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1814259, encodeId=2011181425957, content=<a href='/topic/show?id=ab2894e258a' target=_blank style='color:#2F92EE;'>#适用人群#</a>, objectTitle=Int J Urol：非肌层浸润性膀胱癌患者的分层是否有助于确定根治性膀胱切除术的适用人群？, objectType=article, longId=301683, objectId=7879301683a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7879301683a0, replyNumber=0, likeNumber=0, createdTime=2023-02-03, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7879301683a0, moduleTitle=Int J Urol：非肌层浸润性膀胱癌患者的分层是否有助于确定根治性膀胱切除术的适用人群？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7879301683a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814258, encodeId=4baa181425882, content=<a href='/topic/show?id=ab2894e258a' target=_blank style='color:#2F92EE;'>#适用人群#</a>, objectTitle=美国**广谱抗癌药：治疗有效率75%，在中国适用人群较少, objectType=article, longId=157302, objectId=0c5115e30250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5115e30250, replyNumber=0, likeNumber=33, createdTime=2019-08-10, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5115e30250, moduleTitle=美国**广谱抗癌药：治疗有效率75%，在中国适用人群较少, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c5115e30250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814254, encodeId=5842181425437, content=<a href='/topic/show?id=ab2894e258a' target=_blank style='color:#2F92EE;'>#适用人群#</a>, objectTitle=康弘药业：率先新批pmCNV适应症朗沐适用人群扩大约50%, objectType=article, longId=120946, objectId=e9d812094669, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9d812094669, replyNumber=0, likeNumber=0, createdTime=2018-08-20, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9d812094669, moduleTitle=康弘药业：率先新批pmCNV适应症朗沐适用人群扩大约50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9d812094669)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814257, encodeId=3b36181425ec9, content=<a href='/topic/show?id=ab2894e258a' target=_blank style='color:#2F92EE;'>#适用人群#</a>, objectTitle=葛兰素史克哮喘药物Relvar Ellipta获欧盟批准扩大适用人群, objectType=article, longId=132393, objectId=72881323939f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72881323939f, replyNumber=0, likeNumber=49, createdTime=2019-02-25, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72881323939f, moduleTitle=葛兰素史克哮喘药物Relvar Ellipta获欧盟批准扩大适用人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72881323939f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814255, encodeId=83721814255e4, content=<a href='/topic/show?id=ab2894e258a' target=_blank style='color:#2F92EE;'>#适用人群#</a>, objectTitle=二甲双胍缓释片的应用优势与适用人群解析, objectType=article, longId=121196, objectId=a64e121196d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a64e121196d9, replyNumber=0, likeNumber=38, createdTime=2018-05-02, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a64e121196d9, moduleTitle=二甲双胍缓释片的应用优势与适用人群解析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a64e121196d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814256, encodeId=125518142567e, content=<a href='/topic/show?id=ab2894e258a' target=_blank style='color:#2F92EE;'>#适用人群#</a>, objectTitle=Circulation：年轻成人心肌梗死后心血管风险与他汀适用人群, objectType=article, longId=123131, objectId=58b31231310e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b31231310e, replyNumber=0, likeNumber=28, createdTime=2018-08-10, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b31231310e, moduleTitle=Circulation：年轻成人心肌梗死后心血管风险与他汀适用人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b31231310e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适用人群

2020-05-29

luoxiaog (审核中...)

前往app查看评论内容

#适用人群#

Int J Urol：非肌层浸润性膀胱癌患者的分层是否有助于确定根治性膀胱切除术的适用人群？

2023-02-03

luoxiaog (审核中...)

前往app查看评论内容

#适用人群#

美国**广谱抗癌药：治疗有效率75%，在中国适用人群较少

2019-08-10

luoxiaog (审核中...)

前往app查看评论内容

#适用人群#

康弘药业：率先新批pmCNV适应症朗沐适用人群扩大约50%

2018-08-20

luoxiaog (审核中...)

前往app查看评论内容

#适用人群#

葛兰素史克哮喘药物Relvar Ellipta获欧盟批准扩大适用人群

2019-02-25

luoxiaog (审核中...)

前往app查看评论内容

#适用人群#

二甲双胍缓释片的应用优势与适用人群解析

2018-05-02

luoxiaog (审核中...)

前往app查看评论内容

#适用人群#

Circulation：年轻成人心肌梗死后心血管风险与他汀适用人群

2018-08-10

科室
- - 订阅+
  - 更多科室
工具
服务